spacer
home > pmps > spring 2017 > manufacturing a renaissance
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Manufacturing a Renaissance

The pharmaceutical industry is proud of its technical innovations in the discovery and development of new medicines, and rightly so – for example, the discovery of penicillin and its development as a drug product revolutionised the treatment of infectious diseases. But the pharma industry has sadly fallen far behind in product manufacturing efficiency and innovation. The polymer and foods sectors especially are constantly driving continuous improvement in manufacturing efficiencies, whereas pharma manufacturing practices have not changed significantly in fifty years.

This inertia has been attributed to constraints by regulatory agencies in what are deemed acceptable manufacturing and quality control practices. Batch processing continues to be the normal practice for medicinal products, due to the visibility and control over quality critical factors such as ingredient lots used and processing parameters. However, things are changing.

Implementation of Quality by Design (QbD) principles in product development is resulting in greater emphasis being placed on demonstrating process control through the monitoring of critical process parameters to confirm satisfactory product quality, instead of relying on the traditional approach of the testing of stratified samples. This approach is now considered as ‘best practice’ by regulatory agencies.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

spacer
Robert Harris
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Navigating the new Clinical Trial Regulation with DIA

For those stakeholders involved with clinical trials in Europe, the new Clinical Trial Regulation to be introduced in 2019 will have a dramatic impact. The aim of the change in regulation is to increase the efficiency of all trials in Europe, as well as promoting research while avoiding the duplication of clinical trials
More info >>

White Papers

Clinical Trials in Ukraine: Orange Paper Overview and 1st Half Year 2014

Synergy Research Group

The Orange Paper is an analytical report about the clinical trials market in Russia, published quarterly by the contract research organization Synergy Research Group. The first edition of Orange Paper was released in 2006, and at the moment 31 issues have already published. Now, thanks to Synergy Group Ukraine, obtaining information about the market of clinical trials in Ukraine has become possible. In Ukraine, during the period from 1996 to 2013, applicants had obtained 3,864 positive conclusions about the possibility of conducting clinical trials of drugs, both for domestic and foreign manufacturers, including conduct of multinational multi-center clinical trials (hereinafter – MMCTs)
More info >>

 
Industry Events

Clinical Trial Supply Forum 2018

22-24 January 2018, London, UK

In the constantly changing environment of Clinical Trial Supply, cost efficiency, end to end visibility, logistics and managing complex pipelines are STILL crucial elements that need addressing!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement